Rex TS, Wong Y, Kodali K, Merry S. (2009). Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse. Exp. Eye Res. 89: 735-740. PMCID: PMC2757459

Sullivan T, Rex TS. (2011). Systemic gene delivery protects the photoreceptors in the retinal degeneration slow mouse. J. Neurochem. Res. 36: 613-618.

Sullivan TA, Geisert EE, Hines-Beard J, Rex TS. (2011) Systemic AAV-mediated gene therapy preserves retinal ganglion cells and visual function in DBA/2J glaucomatous mice. J Hum Gene Ther. 22: 1191-1200. pdf

Sullivan TA, Geisert EE, Templeton JP, Rex TS. (2012) Dose-dependent treatment of optic nerve crush by exogenous mutant erythropoietin. Exp. Eye Res. 96: 36-41. PMCID: PMC3350094

Hines-Beard J, Marchetta, J, Gordon S, Chaum E, Geisert EE, Rex TS (2012) A novel mouse model of ocular blast injury. Exp. Eye Res. 99: 63-70. PMCID: PMC3922065. pdf

Hines-Beard J, Desai S, Haag R, D’Surney L, Parker S, Richardson C, Rex TS. (2013) Identification of a therapeutic dose of continuously delivered erythropoietin in the eye using an inducible promoter system. Curr. Gene Ther. 13: 275-281 PMID: 23773177

Bricker-Anthony C, Hines-Beard J, Rex TS. (2014) Molecular changes and delayed vision loss in a mouse model of closed-globe blast trauma. Invest. Ophthalmol. Vis. Sci. 55: 4853-4862 PMCID: PMC4123895

Bricker-Anthony C, Hines-Beard J, D’Surney L, Rex TS. (2014) Ocular blast injury exacerbated by disruption of the blood ocular barrier. J. Neuroinflam. 11:192 PMCID: PMC4264554

de Lucas Cerrillo AM, Bond WS, Rex TS. (in revision) Modified erythropoietin is non-toxic and non-angiogenic in primary cells and adult retina. Gene Therapy